Importantly, with this strategy, 92.5% of HepG2 cells were DAPI+; of those, 100% were ICG+; and, of those, 98.6% were GPC3+, showing the specificity and sensitivity of the panel for identifying liver cancer cells (Figure 3C). The gene discussed is GPC3; the disease is liver cancer.